MedPharm Ltd has expanded its relationship with Novan Inc. through their new agreement, which will broaden the relationship to include development of formulations and selection of product candidates, cost-effective product target screening and the development of in vitro models focused on Novan’s nitric oxide product technology.
 
“MedPharm is delighted to be able to support Novan in advancing and broadening its product pipeline,” commented Eugene Ciolfi, MedPharm’s President & CEO. “Our new agreement allows us to react quickly to changes in requirements and makes full use of MedPharm’s comprehensive services for de-risking Novan’s product development.”
 
“Novan recognizes MedPharm has in-depth experience in developing new topical products fit for commercialization,” added Paula Brown Stafford, Novan’s President and Chief Operating Officer. “The team’s responsiveness, rigorous scientific approach and specialized knowledge makes MedPharm an ideal partner to help Novan achieve its objectives.”